Covid-19 Research

Article Figures

Integrating Serum Biomarkers and Genetic Polymorphisms for Alzheimer’s disease Risk Screening

View article figures, article metadata, topics, DOI, abstract, and related articles from the JBRES article record.

View Abstract Article Library
Article Type: Observational Studies Published: 2025-12-05 Volume/Issue: 6 / 12 Pages: 1865-1876

Integrating Serum Biomarkers and Genetic Polymorphisms for Alzheimer’s disease Risk Screening

Zhizhen Li, Zhaohai Feng, Song He, Huaping Tang, Cai Zhao, Jinfeng Liu, Yao Su, Jiayang Duan, Xue Tian, Yong Yan, Xiaojing Shi and Xueling Bi
Abstract FullText HTML PDF DOI
Alzheimers Neurology Neurological Disorders
Integrating Serum Biomarkers and Genetic Polymorphisms for Alzheimer’s disease Risk Screening
jbres2234-g001.webp

Article Figures

Abstract

<p>Objective: Analyze the differences in the detection results of Alzheimer’s Disease (AD) serum biomarkers and the expression of APOE and SLCO1B1 genotypes, then construct an AD diagnostic model integrating serum biomarkers with APOE and SLCO1B1 genotypes to enhance the sensitivity and specificity of AD screening. <br><br>Methods: Serum samples from 127 participants (41 AD, 39 cognitive impairments, 47 controls) were analyzed for Neurofilament light chain (NF), Aβ42/Aβ40 ratio, p-TAU231, and p-TAU217 via ELISA, combined with APOE/SLCO1B1 genotyping. A nomogram model was constructed using logistic regression and validated by ROC-AUC and Hosmer-Lemeshow tests. <br><br>Results: The AD group showed elevated NF (p &lt; 0.01) and p-TAU231 (p &lt; 0.05), reduced Aβ42/Aβ40 (p &lt; 0.05). APOE ∑4 homozygotes exhibited the highest p-TAU181 (p &lt; 0.001), while SLCO1B1*1b/*1b correlated with increased Aβ42 (p &lt; 0.05). The biomarker model achieved AUC = 0.8365, improving to 0.8832 after genetic integration (calibration p &gt; 0.05). Conclusion: This study pioneers an AD diagnostic model combining serum p-TAU231, NF, and SLCO1B1 polymorphisms, surpassing single-marker limitations (AUC &gt; 0.88). It provides a high-accuracy tool for non-invasive screening and genetic stratification, demonstrating substantial clinical potential.<br></p>

Similar Topic Articles

  • Analysis and Control of Alzheimers Disease Models
    Lakshmi NS*
    Published: 2025-06-16
    Abstract FullText HTML PDF DOI
  • Current Treatments for Parkinsons Disease
    Ayse Aksoy, Duygu Deniz Usta and Atiye Seda Yar Saglam*
    Published: 2024-12-29
    Abstract FullText HTML PDF DOI
  • Limitations of Current Treatment of Alzheimer’s Disease and Proposed Plan to Improve it
    Kedar N Prasad*
    Published: 2024-09-11
    Abstract FullText HTML PDF DOI
  • Diagnosis and Treatment of Alzheimers Disease and Parkinsons Disease with Resonance Medicine
    Praznikov Victor MD, PhD*
    Published: 2022-09-02
    Abstract FullText HTML PDF DOI
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership